ABIN151988

Henze J, Mühlenberg T, Simon S, Grabellus F, Rubin B, Taeger G, Schuler M, Treckmann J, Debiec-Rychter M, Taguchi T, Fletcher JA, Bauer S
PloS one 2012;7(5):e37776

TP53 pathway analysis in paediatric Burkitt lymphoma reveals increased MDM4 expression as the only TP53 pathway abnormality detected in a subset of cases.

Leventaki V, Rodic V, Tripp SR, Bayerl MG, Perkins SL, Barnette P, Schiffman JD, Miles RR
British journal of haematology 2012 Sep;158(6):763-71

Hypoxia activates tumor suppressor p53 by inducing ATR-Chk1 kinase cascade-mediated phosphorylation and consequent 14-3-3γ inactivation of MDMX protein.

Lee JH, Jin Y, He G, Zeng SX, Wang YV, Wahl GM, Lu H
The Journal of biological chemistry 2012 Jun 15;287(25):20898-903

MdmX is required for p53 interaction with and full induction of the Mdm2 promoter after cellular stress.

Biderman L, Poyurovsky MV, Assia Y, Manley JL, Prives C
Molecular and cellular biology 2012 Apr;32(7):1214-25

Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells.

Li D, Marchenko ND, Schulz R, Fischer V, Velasco-Hernandez T, Talos F, Moll UM
Molecular cancer research : MCR 2011 May;9(5):577-88

MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination.

Wang X, Wang J, Jiang X
The Journal of biological chemistry 2011 Jul 8;286(27):23725-34

A small-molecule inhibitor of MDMX activates p53 and induces apoptosis.

Wang H, Ma X, Ren S, Buolamwini JK, Yan C
Molecular cancer therapeutics 2011 Jan;10(1):69-79

c-Abl phosphorylation of Mdm2 facilitates Mdm2-Mdmx complex formation.

Waning DL, Lehman JA, Batuello CN, Mayo LD
The Journal of biological chemistry 2011 Jan 7;286(1):216-22

CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors.

Anderson VE, Walton MI, Eve PD, Boxall KJ, Antoni L, Caldwell JJ, Aherne W, Pearl LH, Oliver AW, Collins I, Garrett MD
Cancer research 2011 Jan 15;71(2):463-72

14-3-3Gamma inhibition of MDMX-mediated p21 turnover independent of p53.

Lee JH, Lu H
The Journal of biological chemistry 2011 Feb 18;286(7):5136-42

Nutlin-3a is a potential therapeutic for ewing sarcoma.

Pishas KI, Al-Ejeh F, Zinonos I, Kumar R, Evdokiou A, Brown MP, Callen DF, Neilsen PM
Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Feb 1;17(3):494-504

The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias.

Kojima K, Burks JK, Arts J, Andreeff M
Molecular cancer therapeutics 2010 Sep;9(9):2545-57

HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea.

Jin G, Cook S, Cui B, Chen WC, Keir ST, Killela P, Di C, Payne CA, Gregory SG, McLendon R, Bigner DD, Yan H
Neuro-oncology 2010 Sep;12(9):956-66

1,25-dihydroxyvitamin D3 enhances the apoptotic activity of MDM2 antagonist nutlin-3a in acute myeloid leukemia cells expressing wild-type p53.

Thompson T, Andreeff M, Studzinski GP, Vassilev LT
Molecular cancer therapeutics 2010 May;9(5):1158-68

Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia.

Long J, Parkin B, Ouillette P, Bixby D, Shedden K, Erba H, Wang S, Malek SN
Blood 2010 Jul 8;116(1):71-80

Smad ubiquitylation regulatory factor 1/2 (Smurf1/2) promotes p53 degradation by stabilizing the E3 ligase MDM2.

Nie J, Xie P, Liu L, Xing G, Chang Z, Yin Y, Tian C, He F, Zhang L
The Journal of biological chemistry 2010 Jul 23;285(30):22818-30

Mage-A cancer/testis antigens inhibit p53 function by blocking its interaction with chromatin.

Marcar L, Maclaine NJ, Hupp TR, Meek DW
Cancer research 2010 Dec 15;70(24):10362-70

An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity.

Wynendaele J, Böhnke A, Leucci E, Nielsen SJ, Lambertz I, Hammer S, Sbrzesny N, Kubitza D, Wolf A, Gradhand E, Balschun K, Braicu I, Sehouli J, Darb-Esfahani S, Denkert C, Thomssen C, Hauptmann S, Lund A, Marine JC, Bartel F
Cancer research 2010 Dec 1;70(23):9641-9

Distinct p53, p53:LANA, and LANA complexes in Kaposi's Sarcoma--associated Herpesvirus Lymphomas.

Chen W, Hilton IB, Staudt MR, Burd CE, Dittmer DP
Journal of virology 2010 Apr;84(8):3898-908

Pharmacologic p53 activation blocks cell cycle progression but fails to induce senescence in epithelial cancer cells.

Huang B, Deo D, Xia M, Vassilev LT
Molecular cancer research : MCR 2009 Sep;7(9):1497-509

MDM2-dependent inhibition of p53 is required for Epstein-Barr virus B-cell growth transformation and infected-cell survival.

Forte E, Luftig MA
Journal of virology 2009 Mar;83(6):2491-9

Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide].

Jobson AG, Lountos GT, Lorenzi PL, Llamas J, Connelly J, Cerna D, Tropea JE, Onda A, Zoppoli G, Kondapaka S, Zhang G, Caplen NJ, Cardellina JH 2nd, Yoo SS, Monks A, Self C, Waugh DS, Shoemaker RH, Pommier Y
The Journal of pharmacology and experimental therapeutics 2009 Dec;331(3):816-26

Full-length hdmX transcripts decrease following genotoxic stress.

Markey M, Berberich SJ
Oncogene 2008 Nov 6;27(52):6657-66

Phosphorylation of MDMX mediated by Akt leads to stabilization and induces 14-3-3 binding.

Lopez-Pajares V, Kim MM, Yuan ZM
The Journal of biological chemistry 2008 May 16;283(20):13707-13

High-resolution array-based comparative genomic hybridization of bladder cancers identifies mouse double minute 4 (MDM4) as an amplification target exclusive of MDM2 and TP53.

Veerakumarasivam A, Scott HE, Chin SF, Warren A, Wallard MJ, Grimmer D, Ichimura K, Caldas C, Collins VP, Neal DE, Kelly JD
Clinical cancer research : an official journal of the American Association for Cancer Research 2008 May 1;14(9):2527-34

Quantitative analyses reveal the importance of regulated Hdmx degradation for p53 activation.

Wang YV, Wade M, Wong E, Li YC, Rodewald LW, Wahl GM
Proceedings of the National Academy of Sciences of the United States of America 2007 Jul 24;104(30):12365-70

RING domain-mediated interaction is a requirement for MDM2's E3 ligase activity.

Kawai H, Lopez-Pajares V, Kim MM, Wiederschain D, Yuan ZM
Cancer research 2007 Jul 1;67(13):6026-30

An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells.

Smalley KS, Contractor R, Haass NK, Kulp AN, Atilla-Gokcumen GE, Williams DS, Bregman H, Flaherty KT, Soengas MS, Meggers E, Herlyn M
Cancer research 2007 Jan 1;67(1):209-17

Hdmx modulates the outcome of p53 activation in human tumor cells.

Wade M, Wong ET, Tang M, Stommel JM, Wahl GM
The Journal of biological chemistry 2006 Nov 3;281(44):33036-44

Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3.

Patton JT, Mayo LD, Singhi AD, Gudkov AV, Stark GR, Jackson MW
Cancer research 2006 Mar 15;66(6):3169-76

No comments: Submit comment

Supportive validation

Submitted by: antibodies-online (provider)
Main image
Experimental details: WB

Supportive validation

Submitted by: antibodies-online (provider)
Main image
Experimental details: WB

Supportive validation

Submitted by: antibodies-online (provider)
Main image
Experimental details: WB

Supportive validation

Submitted by: antibodies-online (provider)
Main image
Experimental details: WB

Supportive validation

Submitted by: antibodies-online (provider)
Main image
Experimental details: FACS